Bellicum Pharmaceuticals Analysis

Bellicum Pink Sheet Analysis Notes

About 29.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellicum Pharmaceuticals recorded a loss per share of 1.57. The entity last dividend was issued on the 6th of February 2020. The firm had 1:10 split on the 6th of February 2020. Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. Bellicum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.The quote for Bellicum Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Bellicum Pharmaceuticals please contact Richard Fair at 281 454 3424 or go to https://www.bellicum.com.

Bellicum Pharmaceuticals Investment Alerts

Bellicum Pharmaceuticals Upcoming and Recent Events

Bellicum Pharmaceuticals Thematic Classifications

Bellicum Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bellicum Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Bellicum Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Bellicum Pharmaceuticals Outstanding Bonds

Bellicum Pharmaceuticals Predictive Daily Indicators

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Bellicum Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bellicum shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Bellicum Pharmaceuticals. By using and applying Bellicum Pink Sheet analysis, traders can create a robust methodology for identifying Bellicum entry and exit points for their positions.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.